Biological Therapies in Osteoarthritis

Author(s): Claire Y.J. Wenham, Michael McDermott, Philip G. Conaghan

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 17 , 2015

Become EABM
Become Reviewer


Given the paucity of effective therapies and the increasing prevalence of osteoarthritis (OA) with ageing and overweight populations, new therapies for this painful, life-impairing condition are desperately needed, for both symptom relief and structural modification. With a growing understanding that OA involves multiple tissue pathologies including inflammation, many more therapeutic targets have been identified. This review will provide a current overview on the role of biologics in OA, including anti-tumour necrosis factor agents, growth factors and interleukin-1 antagonists.

Keywords: Osteoarthritis, tumour necrosis factor, interleukin-1, growth factors, calcitonin gene related peptide, biologics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [2206 - 2215]
Pages: 10
DOI: 10.2174/1381612821666150310144940
Price: $65

Article Metrics

PDF: 55